61 hedge fund portfolios held Teva Pharmaceutical Industries Limited (NYSE:TEVA) at the end of the third quarter which was 68 in the previous quarter. While we acknowledge the potential of Teva ...

As per our database, 61 hedge fund portfolios held Teva Pharmaceutical Industries Limited (NYSE:TEVA) at the end of the third quarter which was 68 in the previous quarter. While we acknowledge the ...

Teva Pharmaceutical Industries' Q4 2024 results ... opportunities presented in the company's pipeline. As mentioned previously, the news from Teva's pipeline has been bright, with Duvakitug ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.78.

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Shares of NYSE TEVA opened at $17.81 on Thursday. Teva Pharmaceutical Industries has a 12 month low of $11.62 and a 12 month high of $22.80. The company has a market cap of $20.17 billion, a P/E ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $21.00. The company’s shares closed ...

In February 2025, Teva Pharmaceuticals and Alvotech announced ... two additional biosimilars and new presentations of two previously partnered products. Alvotech manages development and ...

Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80. The stock has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to ...

This current average has increased by 9.62% from the previous average price target of $26.00. The standing of Teva Pharmaceutical Indus among financial experts becomes clear with a thorough ...

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA). And retail traders should know. We noticed this today when the trades showed up on ...